What is Phathom Pharmaceuticals, Inc.'s treasury stock?

Phathom Pharmaceuticals, Inc. (PHAT) reported treasury stock of $0 in Q1 2026.

What does treasury stock mean?

Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Phathom Pharmaceuticals, Inc. PHAT Treasury Stock

Treasury Stock at other companies

Opko HealthOPK

$1.79M0.0%

Zevra Therapeutics, Inc.ZVRA

$10.98M0.0%

AMP

Amphastar PharmaceuticalsAMPH

$438M+27.3%

Agios PharmaceuticalsAGIO

$802.49M0.0%

Ultragenyx PharmaceuticalRARE

$10M+32.2%

Bristol-Myers SquibbBMY

$43.52B-0.2%

Other financials

Income statement

See full

Revenue$58.3M+104%

Gross profit$46.3M+86.8%

Operating income-$15.5M+80.4%

Net income-$30.4M+67.8%

EPS (diluted)-$0.37+71.8%

Balance sheet

See full

Cash & equivalents$180.9M-14.8%

Total debt$166.3M-18.3%

Total equity-$337.0M+0.4%

Total assets$305.1M+3.7%

Cash flow

See full

Operating cash flow-$15.6M+81.6%

CapEx$61.0K+239%

Free cash flow-$15.7M+81.5%

Valuation

See full

Market cap$824.68M+13.4%

Enterprise value$810.08M+12.7%

P/S4×-4.9×

Profitability

See full

Gross margin84.9%-1.3pp

Operating margin-47.1%-21.9pp

Net margin-76.8%-34.5pp

FCF margin-47.7%-22.1pp

Returns & leverage

See full

Return on equity-147.9%—

Debt / equity5.6×—

Current ratio2.2×-1.4×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s treasury stock?: Phathom Pharmaceuticals, Inc. (PHAT) reported treasury stock of $0 in Q1 2026.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.